Korea Brad Edwards became the first foreign general manager in the Lundbeck Korea’s 23-year history last year, joining from a background at Shire and Takeda across Australia and Singapore. He spoke to us about steering the company’s shift from psychiatry toward neuro-rare disease, the upcoming launch of its new migraine treatment,…
Korea Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get innovative medicines to patients faster and at better prices. The same squeeze on generic margins, combined with new rewards for…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
Korea Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions…
Korea We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum for the affiliate, driven by its fertility and oncology portfolios, as well as an improved access framework for innovative treatments…
Korea Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into innovative medicines, developing multispecific proteins and an oral IBD therapy, and pursuing global expansion. He highlights Korea’s biotech strengths and…
Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Global Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity is enormous, as is the potential impact for government coffers and patients. Can Europe maintain its position as the industry’s…
Korea Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical development, with a focus on TGF-beta and tumour microenvironment targeting. She highlights MP010’s potential, early clinical progress and partnership opportunities,…
Korea I believe we can position Korea as a true global leader in biohealth innovation Lee Hyung Hoon, Vice Minister at Korea’s Ministry of Health and Welfare, outlines his vision for strengthening universal healthcare while positioning Korea as a global biohealth leader. He discusses AI-driven healthcare, regulatory reform, regional access, supply…
Korea We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one of the industry’s most closely watched growth stories. Hyejin Kim, Chairperson of KoNECT, has been at the centre of that…
Korea Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the company, including regional roles based in Tokyo before returning to head the Korean affiliate. He spoke to us about managing…
See our Cookie Privacy Policy Here
